BioDuro Expands in China with New OEB-5 Lab for ADC, PDC, and RDC Synthesis

• BioDuro has opened a new laboratory in Shanghai’s Waigaoqiao Free-Trade Zone for highly potent compound synthesis.

• The OEB-5 lab is designed to support the development of antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), and radionuclide-drug conjugates (RDCs).

BioDuro, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the opening of a specialised laboratory in Shanghai’s Waigaoqiao Free-Trade Zone. The new facility is designed for the synthesis of highly potent compounds at the hundred-gram scale, operating within occupational exposure band 5 (OEB-5).

The lab will support discovery and early development programmes for conjugated drugs, including ADCs, PDCs, and RDCs. Equipped with isolators, closed-system reactors, and a HEPA-filtered HVAC system, it ensures safe handling of highly potent compounds. The facility allows operations within an occupational exposure limit (OEL) as low as 0.1 micrograms per cubic meter, providing a controlled environment for trained technicians.

“The addition of this OEB-5 lab strengthens BioDuro’s capabilities in the development of highly potent drugs,” said Dr. Armin Spura, CEO of BioDuro. “As demand continues to grow for complex conjugated therapeutics, we remain committed to enhancing our capabilities and capacities, providing integrated solutions across chemistry, biology, and DMPK to accelerate the delivery of innovative treatments for global patients.”